Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
暂无分享,去创建一个
A. Harris | J. Baselga | M. Ranson | E. Raymond | F. Rojo | J. Albanell | L. Gianni | S. Kaye | D. Rischin | D. Kieback | H. Swaisland | H. Calvert | S. Averbuch | J. Baselga | T. Björk | A. Feyereislova | D. Kieback | T. Bjork